公开(公告)号：US20240316097A1

公开(公告)日：2024-09-26

申请号：US18677521

申请日：2024-05-29

申请人： Vector Vitale IP LLC

发明人： Max Temnik ,  Sergey Gurin ,  Oleksandr Balakin ,  Peter Novak

IPC分类号： A61K33/30 ,  A23L33/10 ,  A23L33/16 ,  A61K31/704 ,  A61K33/00 ,  A61K33/06 ,  A61K45/06

CPC分类号： A61K33/30 ,  A23L33/10 ,  A23L33/16 ,  A61K31/704 ,  A61K33/00 ,  A61K33/06 ,  A61K45/06

摘要： A pharmaceutical composition is used for improving health, curing abnormalities and degenerative diseases, and achieving anti-aging therapeutic effect in mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective component including at least one of a chemical element in which the isotopic ratio of at least one light isotope is altered to exceed natural abundance.

公开(公告)号：US11986541B2

公开(公告)日：2024-05-21

申请号：US18232013

申请日：2023-08-09

申请人： Vector Vitale IP LLC

发明人： Peter Novak ,  Max Temnik ,  Oleksandr Balakin

IPC分类号： A61K51/04 ,  A61K31/164 ,  A61K33/30 ,  A61P35/00

CPC分类号： A61K51/0476 ,  A61K31/164 ,  A61K33/30 ,  A61P35/00

摘要： A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

公开(公告)号：US20240316098A1

公开(公告)日：2024-09-26

申请号：US18677559

申请日：2024-05-29

申请人： Vector Vitale IP LLC

发明人： Max Temnik ,  Sergey Gurin ,  Oleksandr Balakin ,  Peter Novak

IPC分类号： A61K33/30 ,  A23L33/10 ,  A23L33/16 ,  A61K31/704 ,  A61K33/00 ,  A61K33/06 ,  A61K45/06

CPC分类号： A61K33/30 ,  A23L33/10 ,  A23L33/16 ,  A61K31/704 ,  A61K33/00 ,  A61K33/06 ,  A61K45/06

摘要： A pharmaceutical composition is used for improving health, curing abnormalities and degenerative diseases, and achieving anti-aging therapeutic effect in mammals. The novel pharmaceutical composition includes a pharmaceutical carrier and an isotope selective component including at least one of a chemical element in which the isotopic ratio of at least one light isotope is altered to exceed natural abundance.

公开(公告)号：US12036238B2

公开(公告)日：2024-07-16

申请号：US18238817

申请日：2023-08-28

申请人： Vector Vitale IP LLC

发明人： Peter Novak ,  Max Temnik ,  Oleksandr Balakin

IPC分类号： A61K33/30 ,  A61K33/00 ,  A61K47/54 ,  A61P25/16

CPC分类号： A61K33/30 ,  A61K33/00 ,  A61K47/541 ,  A61P25/16

摘要： Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.